Publications

The Lancet. Haematology

Characterisation of rare haematological immune-related toxicities.

01-01-2019

Cell

NKG2A, a New Kid on the Immune Checkpoint Block.

13-12-2018

The New England journal of medicine

Sunitinib Alone or after Nephrectomy in Renal Cancer.

08-11-2018

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

Annals of oncology : official journal of the European Society for Medical Oncology

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

01-11-2018

Journal of immunotherapy (Hagerstown, Md. : 1997)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

10-10-2018

Journal for immunotherapy of cancer

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

03-10-2018

ESMO open

Report on the status of women occupying leadership roles in oncology.

03-10-2018

ESMO open

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.

03-10-2018

Nature reviews. Clinical oncology

Cytoreductive nephrectomy in metastatic renal cancer - less is more.

01-10-2018

BMC cancer

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

15-09-2018

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Key Publication

Melanoma research

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

01-08-2018

ESMO open

Questions asked in the everyday practice: immune checkpoint inhibitors.

19-07-2018

Anti-cancer drugs

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

01-07-2018

Anti-cancer drugs

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

01-07-2018

Nederlands tijdschrift voor geneeskunde

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

15-06-2018

American journal of clinical dermatology

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

01-06-2018

Melanoma research

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

01-04-2018

ESMO open

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

02-02-2018

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.

01-12-2017

Urology

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

01-11-2017

The New England journal of medicine

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

05-10-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

01-10-2017

The oncologist

Fixed Dosing of Monoclonal Antibodies in Oncology.

01-10-2017

BMC cancer

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

15-09-2017

Cell

Converting Cold into Hot Tumors by Combining Immunotherapies.

07-09-2017

Cancer immunology, immunotherapy : CII

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

01-09-2017

European journal of cancer (Oxford, England : 1990)

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

01-09-2017

Ocular oncology and pathology

Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

01-09-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

01-07-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

01-07-2017

Angiogenesis

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

01-05-2017

JAMA oncology

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

01-04-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

01-04-2017

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

(Neo)adjuvant systemic therapy for melanoma.

01-03-2017

European journal of cancer (Oxford, England : 1990)

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

01-02-2017

Cancer immunology research

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

01-02-2017

Oncoimmunology

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

27-01-2017

Journal of the National Cancer Institute

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

01-01-2017

Journal of clinical pharmacology

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

01-01-2017

Journal of clinical pharmacology

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

01-10-2016

Oncology

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

22-08-2016

World journal of urology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

01-08-2016

Oncoimmunology

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

01-08-2016

Journal of translational medicine

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

25-07-2016

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

BMC cancer

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

11-06-2016

European journal of immunology

Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.

01-06-2016

Characterisation of rare haematological immune-related toxicities.

NKG2A, a New Kid on the Immune Checkpoint Block.

Sunitinib Alone or after Nephrectomy in Renal Cancer.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

Report on the status of women occupying leadership roles in oncology.

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.

Cytoreductive nephrectomy in metastatic renal cancer - less is more.

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

Questions asked in the everyday practice: immune checkpoint inhibitors.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Fixed Dosing of Monoclonal Antibodies in Oncology.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

Converting Cold into Hot Tumors by Combining Immunotherapies.

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

(Neo)adjuvant systemic therapy for melanoma.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.

This site uses cookies